Edition:
United Kingdom

Jounce Therapeutics Inc (JNCE.OQ)

JNCE.OQ on NASDAQ Stock Exchange Global Select Market

3.74USD
12 Dec 2018
Change (% chg)

-- (--)
Prev Close
$3.74
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
77,319
52-wk High
$29.02
52-wk Low
$3.31

Latest Key Developments (Source: Significant Developments)

Jounce Therapeutics Q2 Revenue $225 Million
Thursday, 9 Aug 2018 

Jounce Therapeutics Inc ::JOUNCE THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 REVENUE $225 MILLION.Q2 REVENUE VIEW $12.9 MILLION -- THOMSON REUTERS I/B/E/S.ENDED Q2 WITH $232.7 MILLION IN CASH.JOUNCE THERAPEUTICS - EXPECTS TO NOW BE AT LOWER END OF GROSS CASH BURN GUIDANCE PREVIOUSLY PROVIDED FOR 2018.QTRLY NET LOSS PER SHARE $0.14.JOUNCE THERAPEUTICS - EXPECTS TO END 2018 WITH ABOUT $185.0 TO $195.0 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS.JOUNCE THERAPEUTICS-EXPECTS EXISTING CASH, CASH EQUIVALENTS, INVESTMENTS TO BE SUFFICIENT TO FUND OPERATIONS, CAPEX NEEDS FOR AT LEAST NEXT 24 MONTHS.  Full Article

Jounce Therapeutics Files For Mixed Shelf Of Up To $250 Mln
Thursday, 8 Mar 2018 

March 8 (Reuters) - Jounce Therapeutics Inc ::JOUNCE THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $250 MILLION - SEC FILING.SELLING STOCKHOLDERS MAY SELL UP TO 13.3 MILLION SHARES OF CO'S COMMON STOCK‍​.  Full Article

Jounce Therapeutics reports Q3 loss $0.13/shr
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Jounce Therapeutics Inc :Jounce Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.13.Q3 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S.Jounce Therapeutics Inc- ‍remain on track to announce preliminary efficacy data for phase 1/2 iconic study in 1H 2018​.Jounce Therapeutics Inc - ‍jounce has narrowed its financial guidance previously provided for full year 2017​.Jounce Therapeutics Inc- ‍now expects to use approximately $100.0 million to $110.0 million in cash for full year 2017​.Jounce Therapeutics Inc- ‍collaboration revenue was $18.1 million for Q3 of 2017, compared to $16.9 million for same period in 2016​.Jounce Therapeutics Inc- ‍as of Sept 30, 2017, cash, cash equivalents and investments were $283.4 million, compared to $257.4 million as of Dec 31, 2016​.Jounce Therapeutics - now expects collaboration revenue from non-cash amortization of Celgene upfront payment​ for FY 2017 to be $70 million to $75 million.  Full Article

Partner Fund Management L.P reports 5.4 pct passive stake in Jounce Therapeutics
Friday, 29 Sep 2017 

Sept 29 (Reuters) - Jounce Therapeutics Inc :Partner Fund Management L.P reports 5.4 percent passive stake in Jounce Therapeutics Inc as of Sept 19, 2017 - SEC Filing.  Full Article

Jounce Therapeutics reports Q2 loss of $0.11/shr
Wednesday, 9 Aug 2017 

Aug 9 (Reuters) - Jounce Therapeutics Inc :Jounce Therapeutics reports second quarter 2017 financial results.Q2 loss per share $0.11.Q2 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S.Jounce Therapeutics Inc - ‍ reiterates financial guidance previously provided for full year 2017​.Jounce Therapeutics Inc - ‍ expects to use approximately $100.0 to $120.0 million in cash for full year 2017​.Jounce Therapeutics Inc qtrly ‍collaboration revenue-related party $20.3 million.  Full Article